Eyebright Medical(SH:688050) Zheng Quan Zhi Xing·2025-05-29 12:08Core Viewpoint - The company announced a cash dividend distribution plan for the fiscal year 2024, proposing a cash dividend of 3.50 RMB per 10 shares, which reflects a cautious approach to balancing shareholder returns and the need for reinvestment in growth initiatives [1][2][4]. Profit Distribution Plan - The total cash dividend amount is 87,591,975.59 RMB, representing 22.55% of the net profit attributable to shareholders for 2024, which is 388,402,949.75 RMB [2][4]. - The cash dividend will be based on the total share capital minus shares held in the company's repurchase account, with adjustments made if the total share capital changes before the record date [1][2]. Company Financials - As of December 31, 2024, the company's available distributable profits are 997,112,310.53 RMB for the parent company and 949,502,012.53 RMB for the consolidated financial statements [1][4]. - The company has experienced continuous high growth in revenue and net profit over the past three years, indicating a stable financial condition [5]. Industry Context and Company Strategy - The company operates in the ophthalmic medical device manufacturing sector, focusing on cataract surgery, myopia prevention, and vision care, with a strong position in artificial lenses and orthokeratology lenses [4][5]. - The industry is currently undergoing product upgrades, and the company is expanding its production capacity and market presence, particularly in the contact lens segment [4][5]. Future Plans and Investment - The company plans to retain undistributed profits for expanding production, increasing R&D investment, and exploring new growth points, which is essential for its long-term strategic development [5][6]. - The board of directors has carefully evaluated the profit distribution plan, ensuring it aligns with the company's growth needs and shareholder return expectations [6][7].